Stone House Investment Management’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $42.7K | Buy |
1,521
+1,332
| +705% | +$35.5K | 0.01% | 194 |
|
|
2025
Q4 | $4.71K | Buy |
189
+141
| +294% | +$3.56K | ﹤0.01% | 441 |
|
|
2025
Q3 | $1.22K | Sell |
48
-817
| -94% | -$20.2K | ﹤0.01% | 538 |
|
|
2025
Q2 | $21K | Sell |
865
-2,237
| -72% | -$52.2K | ﹤0.01% | 211 |
|
|
2025
Q1 | $78.6K | Buy |
+3,102
| New | +$81.2K | 0.02% | 112 |
|
|
2024
Q4 | – | Sell |
-5,479
| Closed | -$159K | – | 272 |
|
|
2024
Q3 | $159K | Sell |
5,479
-48
| -0.9% | -$1.4K | 0.03% | 57 |
|
|
2024
Q2 | $155K | Buy |
5,527
+2,188
| +66% | +$60.2K | 0.04% | 59 |
|
|
2024
Q1 | $92.7K | Sell |
3,339
-233
| -7% | -$6.46K | 0.02% | 87 |
|
|
2023
Q4 | $103K | Sell |
3,572
-345
| -9% | -$10.4K | 0.04% | 59 |
|
|
2023
Q3 | $130K | Buy |
3,917
+2
| +0.1% | +$71 | 0.05% | 48 |
|
|
2023
Q2 | $144K | Buy |
3,915
+1
| +0% | +$39 | 0.05% | 45 |
|
|
2023
Q1 | $160K | Buy |
3,914
+2
| +0.1% | +$86 | 0.05% | 45 |
|
|
2022
Q4 | $200K | Sell |
3,912
-774
| -17% | -$37.1K | 0.07% | 43 |
|
|
2022
Q3 | $205K | Buy |
4,686
+1
| +0% | +$49 | 0.1% | 40 |
|
|
2022
Q2 | $246K | Buy |
4,685
+1
| +0% | +$51 | 0.11% | 38 |
|
|
2022
Q1 | $242K | Sell |
4,684
-1,604
| -26% | -$83.2K | 0.08% | 42 |
|
|
2021
Q4 | $371K | Buy |
6,288
+19
| +0.3% | +$941 | 0.13% | 32 |
|
|
2021
Q3 | $246K | Hold |
6,269
| – | – | 0.1% | 34 |
|
|
2021
Q2 | $246K | Sell |
6,269
-26
| -0.4% | -$1.01K | 0.1% | 34 |
|
|
2021
Q1 | $232K | Hold |
6,295
| – | – | 0.12% | 33 |
|
|
2020
Q4 | $232K | Sell |
6,295
-1,173
| -16% | -$43K | 0.12% | 33 |
|
|
2020
Q3 | $260K | Buy |
7,468
+3
| +0% | +$105 | 0.11% | 37 |
|
|
2020
Q2 | $232K | Buy |
7,465
+712
| +11% | +$24.2K | 0.12% | 33 |
|
|
2020
Q1 | $209K | Buy |
6,753
+1
| +0% | +$34 | 0.12% | 30 |
|
|
2019
Q4 | $251K | Buy |
6,752
+1
| +0% | +$36 | 0.18% | 22 |
|
|
2019
Q3 | $230K | Buy |
6,751
+67
| +1% | +$2.44K | 0.11% | 42 |
|
|
2019
Q2 | $275K | Buy |
6,684
+54
| +0.8% | +$2.14K | 0.14% | 37 |
|
|
2019
Q1 | $267K | Sell |
6,630
-134
| -2% | -$5.37K | 0.14% | 43 |
|
|
2018
Q4 | $280K | Sell |
6,764
-470
| -6% | -$19.5K | 0.18% | 43 |
|
|
2018
Q3 | $302K | Buy |
7,234
+57
| +0.8% | +$2.19K | 0.17% | 43 |
|
|
2018
Q2 | $247K | Buy |
7,177
+254
| +4% | +$8.68K | 0.16% | 42 |
|
|
2018
Q1 | $233K | Buy |
6,923
+64
| +0.9% | +$2.2K | 0.15% | 41 |
|
|
2017
Q4 | $236K | Buy |
6,859
+60
| +0.9% | +$2.05K | 0.16% | 36 |
|
|
2017
Q3 | $230K | Sell |
6,799
-828
| -11% | -$26.6K | 0.16% | 36 |
|
|
2017
Q2 | $243K | Buy |
7,627
+76
| +1% | +$2.4K | 0.17% | 35 |
|
|
2017
Q1 | $245K | Buy |
7,551
+70
| +0.9% | +$2.21K | 0.18% | 34 |
|
|
2016
Q4 | $231K | Buy |
+7,481
| New | +$228K | 0.19% | 34 |
|
Other funds holding PFE
VCM
VPM
Stone House Investment Management's PFE Position: Q1 2026 in Review
Stone House Investment Management increased its Pfizer (PFE) stake by 705% in Q1 2026, buying an estimated $35.5K and bringing the position to 1,521 shares worth $42.7K. The position accounts for 0.01% of the portfolio, ranked #194.
Stone House Investment Management first reported a position in PFE in Q4 2016 and has held it in 37 quarters since. The position peaked at $371K in Q4 2021. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- Stone House Investment Management held 1,521 shares of Pfizer worth $42.7K as of Q1 2026.
- Stone House Investment Management bought 1,332 Pfizer shares in Q1 2026, an estimated $35.5K.
- Pfizer made up 0.01% of Stone House Investment Management's portfolio in Q1 2026, its #194 holding.
- Stone House Investment Management first reported a position in Pfizer in Q4 2016 and has held it in 37 quarters since.
- Stone House Investment Management's Pfizer position peaked at $371K in Q4 2021.
- 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.